The Lancet HIV

The Lancet HIV
Title	The Lancet HIV
Discipline	Infectious diseases, HIV/AIDS
Abbreviation	Lancet HIV
Publisher	Elsevier (for The Lancet imprint)
Country	United Kingdom
Frequency	Monthly
History	2014–present

The Lancet HIV The Lancet HIV is a peer-reviewed medical journal focusing on HIV/AIDS, clinical care, public health, and policy related to human immunodeficiency virus. It publishes original research, reviews, commentaries, and commissions aimed at clinicians, researchers, and policymakers active in World Health Organization initiatives, UNAIDS strategies, and global health programmes. The journal forms part of the The Lancet collection alongside sibling titles including The Lancet Oncology, The Lancet Infectious Diseases, and The Lancet Global Health.

Overview

The journal emphasizes translational research bridging antiretroviral therapy developments such as tenofovir and dolutegravir with implementation science in settings influenced by entities like PEPFAR, Global Fund to Fight AIDS, Tuberculosis and Malaria, and national programmes in countries including South Africa, Brazil, India, United States, and United Kingdom. It seeks content relevant to stakeholders at institutions such as Harvard University, University of Oxford, Imperial College London, University of Cape Town, and Johns Hopkins University. Editorial priorities reflect intersections with organizations like Centers for Disease Control and Prevention and research networks including International AIDS Society.

History and development

Launched in 2014, the journal was established during a period marked by advances similar to the rollout of pre-exposure prophylaxis campaigns and large trials led by groups linked to European Commission funding and collaborations with universities like University of California, San Francisco. Early issues featured contributions from investigators affiliated with CDC, WHO, UNAIDS, and research consortia including INSIGHT. The title has evolved alongside landmark events such as the START trial and policy debates prompted by reports from the Institute of Medicine and guidance issued by US Preventive Services Task Force.

Editorial leadership and policies

Editorial leadership has included editors drawn from academic centres such as University College London and advisory input from experts with affiliations to Bill & Melinda Gates Foundation, Wellcome Trust, and national institutes like National Institutes of Health. The journal adheres to editorial policies compatible with standards set by bodies such as the Committee on Publication Ethics and indexing practices aligned with PubMed and Web of Science. It publishes conflict-of-interest disclosures consistent with norms practiced by New England Journal of Medicine and BMJ.

Scope and content

Content encompasses randomized controlled trials similar in scale to multicentre studies run by groups like HIV Prevention Trials Network and PEPFAR-supported operational research. The journal covers topics intersecting with pharmacology of agents such as efavirenz, lopinavir/ritonavir, and raltegravir, as well as epidemiology in regions represented by Sub-Saharan Africa, Southeast Asia, Caribbean, and Latin America. It also publishes analyses related to coinfections including tuberculosis, hepatitis B virus, and cytomegalovirus, and addresses issues involving marginalized populations represented by advocacy groups such as AVAC and clinical networks like MACS.

Impact and reception

Articles from the journal have been cited alongside landmark reports from UNAIDS and policy documents by ministries of health in countries like Kenya, Uganda, and Thailand. Reception among clinicians and policymakers aligns with discourse evident in outlets such as Nature Medicine and The Lancet Oncology, and findings are frequently discussed at conferences including International AIDS Conference, CROI (Conference on Retroviruses and Opportunistic Infections), and meetings convened by International Conference on AIDS and STIs in Africa. The journal’s impact factor contributes to evaluations used by institutions such as Times Higher Education and influences guideline committees including those convened by WHO and national bodies like NICE.

Abstracting and indexing

The journal is abstracted and indexed in major bibliographic databases including PubMed, Scopus, Web of Science, and Embase. It follows metadata practices compatible with repositories such as CrossRef and discovery services used by libraries at institutions like Columbia University, University of Toronto, and McGill University.

Access and publication model

Published by Elsevier under the Lancet imprint, the journal offers subscription and open-access options consistent with hybrid models used by publishers including Springer Nature and Wiley. Open-access articles may be published under Creative Commons licences similar to those employed by PLOS journals, and the journal’s policies reflect funder mandates from organizations such as Wellcome Trust and European Research Council. Manuscript submission and peer review workflows are managed using editorial systems comparable to those used by Elsevier titles and are governed by peer-review standards shared with journals like BMJ.

Category:Medical journals Category:HIV/AIDS